These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 25190434

  • 1. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, Xie Y, Chen C, Chan HL, Zhao M.
    Clin Infect Dis; 2014 Dec 15; 59(12):1714-23. PubMed ID: 25190434
    [Abstract] [Full Text] [Related]

  • 2. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
    Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL, ARES Study Group.
    Hepatology; 2015 May 15; 61(5):1512-22. PubMed ID: 25348661
    [Abstract] [Full Text] [Related]

  • 3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct 15; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 4. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF.
    J Formos Med Assoc; 2018 Jul 15; 117(7):588-597. PubMed ID: 29456079
    [Abstract] [Full Text] [Related]

  • 5. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul 15; 21(7):502-5. PubMed ID: 24074707
    [Abstract] [Full Text] [Related]

  • 6. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z, Zhou F, Zhou Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun 14; 33(6):878-81. PubMed ID: 23803202
    [Abstract] [Full Text] [Related]

  • 8. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 May 14; 21(5):335-9. PubMed ID: 24025132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2016 Nov 14; 88(11):1953-9. PubMed ID: 27017932
    [Abstract] [Full Text] [Related]

  • 12. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA.
    Aliment Pharmacol Ther; 2019 Feb 14; 49(4):448-456. PubMed ID: 30689258
    [Abstract] [Full Text] [Related]

  • 13. Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients.
    Brouwer WP, Sonneveld MJ, Xie Q, Guo S, Zhang N, Zeuzem S, Tabak F, Zhang Q, Simon K, Akarca US, Streinu-Cercel A, Hansen BE, Janssen HL.
    J Viral Hepat; 2016 Jun 14; 23(6):419-26. PubMed ID: 26403919
    [Abstract] [Full Text] [Related]

  • 14. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
    Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, Jiang JN, Xie Q, Dou XG, Sun YT, Li YF, Liu YX, Liu GZ, Ma DW, Chi XL, Tang H, Li XO, Xie Y, Chen XP, Jiang JJ, Zha P, Hou JL, Gao ZL, Fan HM, Ding JG, Zhang DZ, Ren H.
    Zhonghua Gan Zang Bing Za Zhi; 2018 Oct 20; 26(10):756-764. PubMed ID: 30481882
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial.
    Zhou Y, Yan R, Ru GQ, Yu LL, Yao J, Wang H.
    Hepatol Int; 2019 Jul 20; 13(4):422-430. PubMed ID: 31172416
    [Abstract] [Full Text] [Related]

  • 17. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA.
    J Infect Dis; 2017 Apr 01; 215(7):1085-1093. PubMed ID: 28329061
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group.
    Lancet Gastroenterol Hepatol; 2017 Mar 01; 2(3):177-188. PubMed ID: 28404133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.